Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study.
Ahmet BiliciSinan KocaMustafa KaraagacSabin Goktas AydinEmrah EraslanMuhammed Ali KaplanBirol OcakSema Sezgin GoksuSemra PaydasFahri AkgulSumeyye DerinYakup ErgunEmre YekeduzCihan ErolDeniz Tataroglu OzyukselerAtike Gokcen DemirayMustafa KaracaZeynep Gulsum GucSerkan MenekseHavva Yesil CinkirOzge GumusayAbdullah SakinOzlem OzkulHacer DemirDilek ErdemMehmet BesirogluOlcun Umit UnalRamazan AcarLokman KoralSuleyman SahinTeoman SakalarAykut BahceciAhmet OzverenUlug Mutlu GunaydinMehmet Metin SekerVeli SunarPinar DalMehmet ArtacSerdar TurhalPublished in: Journal of cancer research and clinical oncology (2023)
Pazopanib is effective and well-tolerated in treatment of non-adipocytic metastatic STS. Its earlier use (at second-line), good performance status may result in better outcomes. Worldwide scientific collaborations are important to gain knowledge on rarer STS subtypes by conducting studies in larger patient populations.